Logo image of DC4.DE

DEXCOM INC (DC4.DE) Stock Fundamental Analysis

FRA:DC4 - Deutsche Boerse Ag - US2521311074 - Common Stock - Currency: EUR

74.73  -0.32 (-0.43%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to DC4. DC4 was compared to 62 industry peers in the Health Care Equipment & Supplies industry. While DC4 has a great profitability rating, there are some minor concerns on its financial health. DC4 is valued quite expensively, but it does show have an excellent growth rating. These ratings would make DC4 suitable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

DC4 had positive earnings in the past year.
In the past year DC4 had a positive cash flow from operations.
Each year in the past 5 years DC4 has been profitable.
In the past 5 years DC4 always reported a positive cash flow from operatings.
DC4.DE Yearly Net Income VS EBIT VS OCF VS FCFDC4.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

1.2 Ratios

The Return On Assets of DC4 (7.93%) is better than 83.61% of its industry peers.
With an excellent Return On Equity value of 23.61%, DC4 belongs to the best of the industry, outperforming 90.16% of the companies in the same industry.
DC4's Return On Invested Capital of 14.54% is amongst the best of the industry. DC4 outperforms 95.08% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DC4 is above the industry average of 8.23%.
The 3 year average ROIC (11.25%) for DC4 is below the current ROIC(14.54%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.93%
ROE 23.61%
ROIC 14.54%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
DC4.DE Yearly ROA, ROE, ROICDC4.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

With an excellent Profit Margin value of 12.90%, DC4 belongs to the best of the industry, outperforming 81.97% of the companies in the same industry.
DC4's Profit Margin has improved in the last couple of years.
DC4 has a better Operating Margin (16.54%) than 78.69% of its industry peers.
In the last couple of years the Operating Margin of DC4 has grown nicely.
DC4 has a Gross Margin (60.72%) which is comparable to the rest of the industry.
DC4's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 16.54%
PM (TTM) 12.9%
GM 60.72%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
DC4.DE Yearly Profit, Operating, Gross MarginsDC4.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so DC4 is still creating some value.
Compared to 1 year ago, DC4 has more shares outstanding
The number of shares outstanding for DC4 has been increased compared to 5 years ago.
The debt/assets ratio for DC4 has been reduced compared to a year ago.
DC4.DE Yearly Shares OutstandingDC4.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
DC4.DE Yearly Total Debt VS Total AssetsDC4.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

An Altman-Z score of 6.02 indicates that DC4 is not in any danger for bankruptcy at the moment.
DC4's Altman-Z score of 6.02 is amongst the best of the industry. DC4 outperforms 91.80% of its industry peers.
The Debt to FCF ratio of DC4 is 4.35, which is a neutral value as it means it would take DC4, 4.35 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of DC4 (4.35) is better than 68.85% of its industry peers.
A Debt/Equity ratio of 0.57 indicates that DC4 is somewhat dependend on debt financing.
The Debt to Equity ratio of DC4 (0.57) is worse than 60.66% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF 4.35
Altman-Z 6.02
ROIC/WACC1.71
WACC8.53%
DC4.DE Yearly LT Debt VS Equity VS FCFDC4.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 1.50 indicates that DC4 should not have too much problems paying its short term obligations.
DC4 has a Current ratio of 1.50. This is comparable to the rest of the industry: DC4 outperforms 45.90% of its industry peers.
A Quick Ratio of 1.32 indicates that DC4 should not have too much problems paying its short term obligations.
The Quick ratio of DC4 (1.32) is better than 67.21% of its industry peers.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.32
DC4.DE Yearly Current Assets VS Current LiabilitesDC4.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

7

3. Growth

3.1 Past

DC4 shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.60%.
The Earnings Per Share has been growing by 29.25% on average over the past years. This is a very strong growth
DC4 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.11%.
DC4 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.27% yearly.
EPS 1Y (TTM)-0.6%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%0%
Revenue 1Y (TTM)9.11%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%12.49%

3.2 Future

DC4 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.38% yearly.
DC4 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.62% yearly.
EPS Next Y25.28%
EPS Next 2Y25.18%
EPS Next 3Y24.59%
EPS Next 5Y20.38%
Revenue Next Year14.64%
Revenue Next 2Y14.99%
Revenue Next 3Y14.86%
Revenue Next 5Y14.62%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DC4.DE Yearly Revenue VS EstimatesDC4.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
DC4.DE Yearly EPS VS EstimatesDC4.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

DC4 is valuated quite expensively with a Price/Earnings ratio of 51.18.
DC4's Price/Earnings ratio is in line with the industry average.
DC4 is valuated expensively when we compare the Price/Earnings ratio to 25.82, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 32.68 indicates a quite expensive valuation of DC4.
The rest of the industry has a similar Price/Forward Earnings ratio as DC4.
The average S&P500 Price/Forward Earnings ratio is at 21.76. DC4 is valued rather expensively when compared to this.
Industry RankSector Rank
PE 51.18
Fwd PE 32.68
DC4.DE Price Earnings VS Forward Price EarningsDC4.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as DC4.
DC4's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 57.61
EV/EBITDA 34.33
DC4.DE Per share dataDC4.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DC4 does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of DC4 may justify a higher PE ratio.
A more expensive valuation may be justified as DC4's earnings are expected to grow with 24.59% in the coming years.
PEG (NY)2.02
PEG (5Y)1.75
EPS Next 2Y25.18%
EPS Next 3Y24.59%

More info and screens

0

5. Dividend

5.1 Amount

DC4 does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DEXCOM INC

FRA:DC4 (5/23/2025, 7:00:00 PM)

74.73

-0.32 (-0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-23 2025-07-23/amc
Inst Owners96.25%
Inst Owner ChangeN/A
Ins Owners0.35%
Ins Owner ChangeN/A
Market Cap29.30B
Analysts86.06
Price Target90.06 (20.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.87%
Min EPS beat(2)-11.66%
Max EPS beat(2)-4.09%
EPS beat(4)2
Avg EPS beat(4)-1.25%
Min EPS beat(4)-11.66%
Max EPS beat(4)9.24%
EPS beat(8)6
Avg EPS beat(8)14.5%
EPS beat(12)9
Avg EPS beat(12)12.8%
EPS beat(16)11
Avg EPS beat(16)12.29%
Revenue beat(2)0
Avg Revenue beat(2)-0.7%
Min Revenue beat(2)-1.2%
Max Revenue beat(2)-0.19%
Revenue beat(4)0
Avg Revenue beat(4)-2.01%
Min Revenue beat(4)-4.99%
Max Revenue beat(4)-0.19%
Revenue beat(8)2
Avg Revenue beat(8)-0.7%
Revenue beat(12)4
Avg Revenue beat(12)-0.65%
Revenue beat(16)6
Avg Revenue beat(16)-0.11%
PT rev (1m)-6.46%
PT rev (3m)-5.66%
EPS NQ rev (1m)-6.02%
EPS NQ rev (3m)-6.27%
EPS NY rev (1m)0.35%
EPS NY rev (3m)0.48%
Revenue NQ rev (1m)-0.52%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0.23%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 51.18
Fwd PE 32.68
P/S 7.99
P/FCF 57.61
P/OCF 34.37
P/B 14.62
P/tB 15.43
EV/EBITDA 34.33
EPS(TTM)1.46
EY1.95%
EPS(NY)2.29
Fwd EY3.06%
FCF(TTM)1.3
FCFY1.74%
OCF(TTM)2.17
OCFY2.91%
SpS9.35
BVpS5.11
TBVpS4.84
PEG (NY)2.02
PEG (5Y)1.75
Profitability
Industry RankSector Rank
ROA 7.93%
ROE 23.61%
ROCE 18.47%
ROIC 14.54%
ROICexc 53.32%
ROICexgc 60.37%
OM 16.54%
PM (TTM) 12.9%
GM 60.72%
FCFM 13.87%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexcg growth 3Y55.18%
ROICexcg growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score6
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF 4.35
Debt/EBITDA 1.42
Cap/Depr 172.69%
Cap/Sales 9.38%
Interest Coverage 250
Cash Conversion 105.79%
Profit Quality 107.47%
Current Ratio 1.5
Quick Ratio 1.32
Altman-Z 6.02
F-Score6
WACC8.53%
ROIC/WACC1.71
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.6%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%0%
EPS Next Y25.28%
EPS Next 2Y25.18%
EPS Next 3Y24.59%
EPS Next 5Y20.38%
Revenue 1Y (TTM)9.11%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%12.49%
Revenue Next Year14.64%
Revenue Next 2Y14.99%
Revenue Next 3Y14.86%
Revenue Next 5Y14.62%
EBIT growth 1Y2.68%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year76.73%
EBIT Next 3Y37.42%
EBIT Next 5Y29.37%
FCF growth 1Y38.27%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y27.88%
OCF growth 3Y30.77%
OCF growth 5Y25.76%